

Big Bets. Bold Research. Best Outcomes.

The Parker Institute for Cancer Immunotherapy is an unprecedented collaboration among the country's best researchers, clinicians and industry leaders.

At the Parker Institute, we imagine a world where cancer is curable. We are making this a reality by transforming the way research is done. We bring together the top minds in cancer immunotherapy. We fund the boldest ideas that will lead to breakthrough discoveries. And we give our researchers the most innovative tools and resources to fuel their discoveries. Our goal: *to accelerate the development of breakthrough immune therapies to turn cancer into a curable disease.*

By the numbers



6 Centers*



40+ Industry and
Nonprofit Partners



300+ Nation's
Top Researchers



4 Clinical Trials



60+ Labs



5 Fellows & Scholars

**The centers include Memorial Sloan Kettering Cancer Center, Stanford Medicine, The University of California, Los Angeles, The University of California, San Francisco, The University of Pennsylvania and The University of Texas MD Anderson Cancer Center.*

Make big bets to make the biggest impact

The Parker Institute **funds high-risk, high-reward research projects** in areas that hold the most promise for advancing cancer immunotherapy and helping patients.



- **Best-in-class T-cells:** We advance the next generation of T-cell therapies to provide targeted, safe, long-lasting treatments that can conquer cancer.
- **Checkpoint Inhibitor Resistance:** We uncover why some patients respond to immunotherapy while others may not, in order to overcome cancer drug resistance.
- **Tumor Antigen Discovery:** We pinpoint novel cancer cell markers that will become the foundation for new therapies and personalized treatments.
- **Tumor Microenvironment:** We discover how tumors impair immune cells, which will jumpstart the creation of therapies that can fight hard-to-treat solid tumors.

Fuel bold research with robust infrastructure

The Parker Institute provides innovative tools and resources that aren't widely available so our researchers can do their most ambitious work.

- Our **clinical trials management team** works with our six research centers to lead larger, multi-site clinical trials. We adopted an agreement with our centers that expedites the approval of multi-center clinical trials, **saving both time and money**.
- The Parker Institute **manages the intellectual property collaboratively** with representatives from each academic institution from discovery to commercialization to **ensure patients benefit from discoveries** as soon as possible.
- Parker Institute data scientists work with our researchers **to interpret their data and accelerate research**. We also use **advanced analytic tools** to provide immune context and help our investigators **get the most out of their data**.
- Our investigators have **access to cutting-edge technology and machines**. They also have access to discounts on supplies and equipment to ensure they have the tools they need for their research.

Key clinical trials and projects

 Opportunity	 Progress
Foster collaboration to identify the best technology	The Parker Institute and the Cancer Research Institute launched a global collaboration of more than 35 leading cancer neoantigen research groups to advance personalized cancer treatments through neoantigen discovery.
Investigate checkpoint inhibitor resistance in melanoma patients	Through our first trial to involve all six research centers, we are taking a laser-focused approach to understand how combinations work in treating melanoma, as well as why some patients benefit from treatments while others do not.
Tackle difficult cancers	We are leveraging our network of experts, using innovative technology and adding immunotherapy to the standard of care to treat aggressive tumor types.
Use innovative technology to treat patients	The Parker Institute is helping fund the first-in-human U.S. study of CRISPR technology, which will use new technology to engineer longer-lasting killer T-cells for more efficient and effective therapy.